证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2022-013 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------------------|--------------|-------|-----------------------------------------------|-------|--------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | \n \n | | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | | | | | | | 国海证券组织的电话会议。参加人员主要如下： | | | | | 国海证券 | 周小刚、郭磊 | | | | | | | 安信基金 | 英正达 | | 北京诺昌投资 | | 许耀文 | | | 博道基金 | 邓韵阳 | | 北京远惟投资 | | 张翠双 | | | | | ...

Financial Performance - In the first three quarters of 2022, the company achieved a revenue of 1.605 billion CNY, with a net profit of 485.2 million CNY, representing a year-on-year growth of 15.67% and 45.10% respectively [2] - The revenue for the third quarter was 1.819 billion CNY, with a year-on-year growth of 35% [2] - The revenue for the first three quarters of 2022 was 534 million CNY, 545 million CNY, and 526 million CNY respectively, showing a slight decrease in the third quarter compared to the previous two [3] Market Strategy - The company has expanded its target market for its product "Yikexin" from ages 0-3 to 0-6, increasing the potential customer base by 1.5 times [3] - The online sales channel is primarily driven by the pink packaging, while the green packaging is also experiencing growth despite a declining birth rate [4] Cost Management - The company's expense ratio decreased by 3% in the third quarter compared to the first half of the year, attributed to significant revenue growth diluting fixed costs [3] - The gross profit margin remains stable at around 80%, with no significant changes expected in the near future [3] Product Development - The company is focusing on technological innovation and has made progress in building innovation platforms to lead sustainable high-quality development [2] - Research and development expenses are expected to remain stable, aligned with the company's strategic goals [4] Sales Channels - The sales distribution is approximately 15% from hospitals and 85% from outside hospitals, with online penetration around 15-20% [3] - The company is cautious about external investments and currently has no clear acquisition plans [4] Future Outlook - The company anticipates maintaining a revenue growth rate of around 30% in the coming years, supported by new product promotions [3] - The company is prepared to adapt its marketing strategies in response to market changes and competitive pressures [4]

Financial Performance - For the first nine months of 2022, the company achieved a revenue of CNY 1.819 billion, representing a year-on-year growth of 15.67%[5] - The net profit attributable to shareholders for the same period was CNY 462 million, an increase of 45.10% compared to the previous year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported a revenue of CNY 526 million in Q3 2022, up 33.58% year-on-year, and a net profit of CNY 283 million, which is a 68.83% increase[5] - The net profit for the first nine months was CNY 865 million, a 46.22% increase driven by growth in the pharmaceutical business[15] - The net profit for the third quarter was 865,038,482.33 CNY, an increase of 46.1% compared to 591,605,152.82 CNY in the same period last year[30] - The total comprehensive income attributable to the parent company's owners was 462,412,455.71 CNY, compared to 318,686,318.58 CNY in the previous year, reflecting a growth of 45%[30] - The company reported a total profit of 1,009,123,751.74 CNY, up from 693,224,944.16 CNY year-over-year, representing a 45.5% increase[30] Assets and Liabilities - The total assets of the company at the end of the reporting period reached CNY 4.595 billion, a growth of 16.76% from the end of the previous year[7] - Total liabilities rose to CNY 666,435,393.06, compared to CNY 536,028,235.88, marking an increase of 24.3%[26] - The equity attributable to shareholders increased to CNY 2.520 billion, reflecting a year-on-year growth of 12.25%[7] - The equity attributable to shareholders increased to CNY 2,519,636,676.14 from CNY 2,244,689,408.43, a growth of 12.2%[26] - The company's retained earnings reached CNY 2,094,102,952.03, up from CNY 1,819,155,684.32, reflecting an increase of 15.1%[26] Cash Flow and Investments - The net cash flow from operating activities for the first nine months was CNY 945 million, showing a growth of 55.40% year-on-year[7] - Cash flow from operating activities generated a net amount of 945,513,109.09 CNY, compared to 608,444,452.56 CNY in the same period last year, indicating a 55.4% increase[33] - Investment activities resulted in a net cash outflow of 98,191,382.59 CNY, an improvement from a net outflow of 962,673,685.57 CNY in the same period last year[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,742[16] - Shandong Huate Holding Group Co., Ltd. holds 22.00% of shares, totaling 51,544,340 shares[16] - Hong Kong Central Clearing Limited holds 3.03% of shares, totaling 7,106,965 shares[16] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[16] - The company has not reported any pledged or frozen shares among the top shareholders[16] - The report indicates no known relationships or concerted actions among the major shareholders[19] Operational Highlights - Total operating revenue for the third quarter was CNY 1,818,732,732.71, an increase of 15.7% compared to CNY 1,572,409,826.06 in the same period last year[26] - Total operating costs decreased to CNY 831,485,865.51 from CNY 906,185,041.84, representing a reduction of approximately 8.2%[26] - The company reported a significant increase in accounts receivable by 70.73% to CNY 101 million, attributed to the growth in sales revenue[12] - The company’s contract liabilities rose by 73.88% to CNY 190 million, indicating an increase in advance payments received[15] - The company reported a significant increase in accounts payable, which rose to CNY 32,729,985.06 from CNY 70,563,649.54, indicating a decrease of 53.7%[23] Future Plans - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[28] Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.67, marking a 76.36% increase compared to the same period last year[7] - Basic and diluted earnings per share were both 1.97 CNY, up from 1.36 CNY year-over-year[32]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,225,199,135.70, representing a 21.15% increase compared to CNY 1,011,340,076.40 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 304,643,012.93, up 32.90% from CNY 229,228,221.75 in the previous year[25]. - The net cash flow from operating activities reached CNY 604,737,351.83, a significant increase of 79.03% compared to CNY 337,780,624.10 in the same period last year[25]. - Basic earnings per share increased to CNY 1.30, reflecting a growth of 32.65% from CNY 0.98 in the previous year[25]. - The gross profit margin for the pharmaceutical products segment improved by 1.65 percentage points to 87.08%, with revenue from pharmaceutical products increasing by 44.10% year-on-year[54]. - The company reported a significant increase in revenue from its subsidiary, achieving ¥1,078,872,408.44 in operating income, a 44.10% increase year-on-year[70]. - Net profit from the subsidiary reached ¥548,149,261.31, reflecting a 39.85% growth compared to the same period last year[70]. - The company reported a significant increase in cash flow from operating activities, amounting to CNY 604,737,351.83, a 79.03% increase from CNY 337,780,624.10 in the previous year, attributed to higher sales collections[51]. Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 4,232,886,535.35, which is a 7.56% increase from CNY 3,935,426,876.64 at the end of the previous year[25]. - The total current assets as of June 30, 2022, amounted to CNY 2,707,741,547.42, an increase from CNY 2,411,163,790.74 on January 1, 2022, reflecting a growth of approximately 12.3%[144]. - Total liabilities rose to ¥598,792,681.73, compared to ¥536,028,235.88, indicating an increase of about 11.7%[150]. - The company's equity attributable to shareholders rose to ¥2,361,867,233.36 from ¥2,244,689,408.43, an increase of approximately 5.2%[150]. - The total owner's equity reached ¥3,634,093,853.62, up from ¥3,399,398,640.76, indicating an increase of approximately 6.9%[150]. Research and Development - The company increased its R&D investment to CNY 35,406,415.39, which is an 18.71% rise from CNY 29,827,217.69 in the previous year, reflecting a commitment to enhancing its product offerings[51]. - The company has established a children's drug research center and has completed five major pediatric drug development tasks under the national "13th Five-Year" plan[42]. - Dain Pharmaceutical has focused on the pediatric pharmaceutical and health industry since 2007, aiming to enhance its competitive advantage in this field[76]. - The company has established a Children's Drug Technology Center in Rongcheng and a Children's Drug Research Institute in Beijing to enhance R&D capabilities[76]. Market and Product Development - The company's main business is in the pharmaceutical sector, with revenue from the pharmaceutical industry amounting to 1.079 billion CNY, accounting for 88.06% of total revenue[33]. - The product line includes well-known brands such as "Yikexin," which has maintained the highest market share in its category for many years[33]. - The company has implemented a brand extension strategy to expand its children's health product chain, including health foods and supplements[33]. - The pediatric health products include various formulations such as oral liquids, granules, and topical ointments, tailored for children's needs[33]. - The company has expanded the usage age of "Yike Xin" vitamin AD from 0-3 years to 0-6 years, further increasing market potential[42]. Strategic Initiatives - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company aims to enhance its market presence through professional market operations and a nationwide sales network[33]. - Market expansion efforts are underway, with plans to enter H markets by the end of the year, targeting an increase in market share by J%[36]. - Strategic partnerships have been established with M, expected to enhance distribution channels and increase sales by N%[36]. - The company is focusing on sustainability initiatives, committing $O million to improve environmental impact and reduce carbon footprint[36]. Challenges and Risks - In the first half of 2022, the company faced challenges due to the COVID-19 pandemic but managed to achieve record high performance through strategic planning and employee motivation[42]. - The company faces challenges in pediatric pharmaceuticals due to the complexity of clinical trials and regulatory requirements, but anticipates increased government support for pediatric drug development[73]. Investor Relations - The company held over ten large-scale conference calls with analysts and investors, demonstrating its commitment to investor relations management[45]. - The company emphasizes the importance of reading the full report, particularly the section on risks and countermeasures[5]. Miscellaneous - The company did not undergo an audit for the semi-annual financial report[99]. - There were no significant litigation or arbitration matters during the reporting period[101]. - The company reported no major related party transactions in daily operations[104].

Financial Performance - The company's revenue for Q1 2022 was ¥605,516,557.27, representing a 23.74% increase compared to ¥489,326,504.49 in the same period last year[4] - Net profit attributable to shareholders for Q1 2022 was ¥156,021,080.23, up 43.18% from ¥108,966,290.01 in Q1 2021[4] - Basic earnings per share for Q1 2022 were ¥0.67, a 42.55% increase from ¥0.47 in Q1 2021[4] - Operating profit for Q1 2022 was ¥345,797,233.28, up 42.0% from ¥243,874,893.81 in the same period last year[22] - The net profit after deducting non-recurring gains and losses was ¥155,708,478.77, which is a 45.80% increase from ¥106,799,559.07 in the same period last year[4] Cash Flow - The net cash flow from operating activities increased by 102.02%, reaching ¥276,299,060.18 compared to ¥136,767,795.21 in the previous year[4] - The net cash flow from operating activities for Q1 2022 was ¥276,299,060.18, a significant increase of 102.3% compared to ¥136,767,795.21 in the same period last year[26] - Cash received from sales of goods and services was ¥670,887,451.35, up from ¥579,666,292.74 in the previous year, reflecting a growth of 15.7%[26] - Cash paid for purchasing goods and services decreased to ¥52,690,791.18 from ¥120,335,520.50, a reduction of 56.2%[26] - The cash flow from operating activities totaled ¥687,190,815.22, compared to ¥593,516,866.95 in the same period last year, marking an increase of 15.8%[26] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥4,317,462,526.81, reflecting a 9.71% increase from ¥3,935,426,876.64 at the end of the previous year[4] - Total liabilities rose to ¥623,824,218.28, compared to ¥536,028,235.88, marking an increase of 16.3%[22] - Total current assets reached ¥2,798,260,444.65, up from ¥2,411,163,790.74 at the beginning of the year[16] - Cash and cash equivalents amounted to ¥1,540,661,180.06, an increase from ¥1,223,433,930.52 at the beginning of the year[16] Shareholder Information - Total number of common shareholders at the end of the reporting period was 13,573[12] - The company has a significant shareholder, Shandong Huate Holding Group Co., Ltd., holding 22.00% of shares[12] - The top ten shareholders include various institutional investors, indicating a diverse ownership structure[12] - The company has not disclosed any related party relationships among its major shareholders[15] Research and Development - Research and development expenses for Q1 2022 totaled ¥12,769,669.95, a rise from ¥11,043,104.80 in Q1 2021[22] Strategic Outlook - The increase in revenue was primarily driven by the growth in profits from the subsidiary, Dain Pharmaceutical[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] - There are no significant new strategies or product developments mentioned in the report[18] Non-Recurring Items - The company reported a total of ¥312,601.46 in non-recurring gains for the period[6] - The company did not undergo any retrospective adjustments or restatements of previous years' financial data[4]

Financial Performance - The company's operating revenue for 2021 was CNY 2,027,141,972.94, an increase of 11.32% compared to CNY 1,821,033,958.04 in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 380,262,703.21, representing a growth of 30.78% from CNY 290,756,639.28 in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 356,264,194.12, up 33.51% from CNY 266,850,960.99 in 2020[22]. - The basic earnings per share for 2021 was CNY 1.62, a 30.65% increase from CNY 1.24 in 2020[22]. - The total assets at the end of 2021 were CNY 3,935,426,876.64, an increase of 6.51% from CNY 3,694,977,604.81 at the end of 2020[22]. - The net assets attributable to shareholders at the end of 2021 were CNY 2,244,689,408.43, up 14.96% from CNY 1,952,595,837.52 at the end of 2020[22]. - The net cash flow from operating activities for 2021 was CNY 755,852,593.24, a slight increase of 2.76% from CNY 735,551,506.32 in 2020[22]. - The weighted average return on equity for 2021 was 18.09%, an increase of 2.30 percentage points from 15.79% in 2020[22]. Revenue Breakdown - The company's revenue from the pharmaceutical industry was CNY 1.473 billion, accounting for 72.65% of total operating income[34]. - In 2021, the pharmaceutical business accounted for 72.65% of the company's total revenue, with profits from Dain Pharmaceutical contributing 90.95% to the net profit attributable to shareholders[40]. - The pharmaceutical products segment generated CNY 1.47 billion, accounting for 72.65% of total revenue, with a year-on-year growth of 31.01% driven by increased sales of key products[46]. - The electronic information products segment saw a revenue increase of 50.46%, reaching CNY 33.17 million, primarily due to growth in technical service income[52]. - The education segment reported a revenue of CNY 222.24 million, with a year-on-year growth of 5.67%[51]. Strategic Focus - The company focuses on children's health products, with a product portfolio that includes leading brands such as Yike Xin, which has maintained the highest market share in its category[35]. - The company has established a modern production base for children's medicine in Rongcheng, Shandong, designed specifically for the needs of pediatric drug development and production[35]. - The company is committed to innovation in the pharmaceutical industry, aligning with national policies that emphasize the development of innovative drugs and vaccines[33]. - The company is positioned to benefit from the growing demand for pediatric medications, supported by favorable government policies[33]. - The company has restructured its strategy to focus on children's medication and health, changing its name to "Shandong Huate Dain Health Co., Ltd." to reflect this new direction[44]. Governance and Compliance - The company has maintained an A rating in information disclosure assessments for nine consecutive years, demonstrating strong compliance and governance practices[45]. - The company has revised and improved over 100 internal regulations to enhance corporate governance and compliance with state-owned enterprise management standards[45]. - The company has established a clear separation of business, personnel, assets, and finances from its controlling shareholder, ensuring operational independence[103]. - The company has implemented a performance evaluation system for senior management that combines quantitative and qualitative assessments, linking compensation to performance targets[98]. - The company has established a risk management framework across its subsidiaries to address operational risks[145]. Research and Development - The company has a specialized children's drug research institute to promote the development of tailored pediatric medications[35]. - The company is committed to increasing R&D investment to improve its product series, particularly in therapeutic products, which are currently limited[90]. - The company is developing several new products, including a drug for ADHD and a treatment for hand-foot-mouth disease, which are expected to enrich the product line[64]. - R&D investment amounted to ¥82,106,389.63, which is 4.05% of operating revenue, down from 6.65% the previous year[64]. - The number of R&D personnel decreased by 11.16% to 215, with a notable drop in master's degree holders by 30.77%[64]. Environmental Responsibility - The company has implemented measures to ensure compliance with environmental regulations, with no administrative penalties reported during the reporting period[159]. - The company achieved a total discharge of 1.33 tons of COD and 0.02 tons of ammonia nitrogen, well within the permitted limits[155]. - The company has established an emergency response plan for environmental incidents, which has been filed with the environmental protection department[159]. - The company has taken measures to reduce carbon emissions, including energy-saving initiatives and adjustments in production processes[159]. - The company actively fulfills its responsibilities as a state-owned listed company, contributing to social welfare by sponsoring 100 students from underprivileged families each year[160]. Shareholder Engagement - The company plans to distribute a cash dividend of CNY 8.00 per 10 shares to all shareholders based on the total share capital as of December 31, 2021[6]. - The company reported a cash dividend of 8.00 CNY per 10 shares, totaling 187,465,188 CNY for the year, which represents 100% of the total profit distribution[142]. - The company held its annual general meeting on April 22, 2021, with a participation rate of 22.26%[104]. - The first extraordinary general meeting in 2021 took place on August 17, 2021, with a participation rate of 46.17%[104]. - The second extraordinary general meeting in 2021 was held on November 26, 2021, with a participation rate of 42.80%[104]. Management Changes - The company experienced a change in management with the appointment of new directors and the departure of several key personnel, including the general manager and financial director, on August 17, 2021[111]. - The independent director, Deng Yan, completed her term after serving for six years, highlighting a governance change within the board[109]. - The company has maintained a stable board composition with no new external appointments during the reporting period[106]. - The overall governance structure remains intact with the election of new directors to replace those who completed their terms[111]. - The company has a strong leadership team with key positions held by individuals with extensive experience in the pharmaceutical and technology industries[118].

证券代码：000915 证券简称：华特达因 公告编号：2021-053 山东华特达因健康股份有限公司 关于参加"山东辖区上市公司 2021 年度投资者网上 集体接待日"活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为加强与广大投资者的沟通交流，山东华特达因健康股份有限 公司（以下简称"公司"）将参加由山东证监局、山东上市公司协会 联合举办并由深圳市全景网络有限公司承办的"山东辖区上市公司 2021 年度投资者网上集体接待日活动"，现将有关事项公告如下： 一、 活动时间 2021 年 11 月 16 日（星期二）14:00 至 16:00。 二、活动方式 本次投资者网上集体接待日活动将通过深圳市全景网络有限公 司提供的网上平台，采取线上交流的方式进行。投资者可以登录"全 景·路演天下"网站（http://rs.p5w.net）参与本次活动。 三、公司出席本次活动人员 董事会秘书范智胜先生、财务总监王伟女士、会计机构负责人刘 稳女士、证券事务代表王春阳先生将参加本次投资者网上集体接待日 活动，与投资者进行在线交流。欢迎广大投资者积极参与。 特此公告 ...

Revenue and Profit - Revenue for Q3 2021 reached ¥561,069,749.66, an increase of 5.06% year-over-year, while year-to-date revenue was ¥1,572,409,826.06, up 15.04% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥89,458,096.82, a decrease of 3.26% year-over-year, with year-to-date net profit at ¥318,686,318.58, reflecting a significant increase of 40.10%[4] - Total operating revenue for the first nine months of 2021 reached ¥1,572,409,826.06, an increase of 15.06% compared to ¥1,366,784,708.25 in the same period last year[25] - Net profit for the same period was ¥591,605,152.82, up 41.67% from ¥417,407,220.10 in the previous year[26] - Earnings per share increased to ¥1.36, compared to ¥0.97 in the prior year[26] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.35, down 10.26% from the previous year, while year-to-date earnings per share increased by 40.21% to ¥1.36[4] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥3,958,570,957.80, representing a growth of 7.13% from the end of the previous year[4] - The company's total current assets as of September 30, 2021, amount to ¥2,524,244,327.25, an increase from ¥2,283,523,247.68 at the end of 2020[16] - The total assets of the company as of September 30, 2021, are ¥3,958,570,957.80, compared to ¥3,694,977,604.81 at the end of 2020[19] - The total liabilities decreased to ¥662,083,749.86 from ¥759,722,919.94 year-over-year[19] - The company’s total liabilities and equity reached ¥3,296,487,207.94, up from ¥2,935,254,684.87 in the previous year[22] Shareholders' Equity - Shareholders' equity attributable to the parent company reached ¥2,189,266,136.35, an increase of 12.12% compared to the end of the previous year[4] - The total equity attributable to shareholders increased to ¥2,189,266,136.35 from ¥1,952,595,837.52 year-over-year[22] Cash Flow - The company reported a net cash flow from operating activities of ¥608,444,452.56, which is an increase of 11.72% year-over-year[4] - The company reported a net cash flow from operating activities of ¥608,444,452.56, compared to ¥544,635,637.20 in the previous year[29] - Investment activities resulted in a net cash outflow of ¥962,673,685.57, compared to a net outflow of ¥567,526,829.39 in the same period last year[30] Financial Performance - The company’s operating costs for the first nine months were ¥906,185,041.84, slightly up from ¥897,584,161.50 in the previous year[25] - The company’s financial expenses showed a significant improvement, with a net income of ¥7,880,527.55 compared to a loss of ¥3,592,181.83 in the previous year[25] Inventory and Payables - The company's inventory increased to ¥153,207,735.15 from ¥134,720,911.39 year-over-year[16] - The accounts payable decreased to ¥149,681,160.95 from ¥181,237,029.74 year-over-year[19] Other Financial Metrics - Non-recurring gains and losses totaled ¥8,024,887.92 for Q3 2021, with government subsidies contributing ¥2,062,423.39 and gains from financial assets amounting to ¥6,926,729.38[6] - The company experienced a significant increase in prepayments, which rose by 91.46% to ¥35,401,472.64, attributed to increased advance payments[7] - Financial expenses increased by 110.05% to -¥7,545,380.39, primarily due to higher interest income[7] - The company’s cash and cash equivalents decreased by 41.75% to ¥869,167,297.32, mainly due to investments in bank wealth management products[7] - Cash and cash equivalents decreased to ¥869,167,297.32 from ¥1,492,016,051.09 year-over-year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,863, with the top 10 shareholders holding 36.77% of the shares[12] - Shandong Huate Holding Group Co., Ltd. is the largest shareholder, owning 22.00% of the shares, equivalent to 51,544,340 shares[12] Product Development and Strategy - The company has not disclosed any new product developments or market expansion strategies in the current report[12]

Financial Performance - The company's operating revenue for the reporting period reached ¥1,011,340,076.40, representing a 21.45% increase compared to ¥832,723,482.58 in the same period last year[25]. - Net profit attributable to shareholders was ¥229,228,221.75, a significant increase of 69.80% from ¥134,998,363.12 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥221,394,750.77, up 73.07% from ¥127,921,739.31 year-on-year[25]. - Basic earnings per share increased to ¥0.98, up 68.97% from ¥0.58 in the same period last year[25]. - The net profit for the period was ¥421,598,252.16, marking a significant increase of 68.54% from ¥250,143,506.03, primarily due to profit growth from the subsidiary, Dain Pharmaceutical[44]. - The company's operating profit for the first half of 2021 was CNY 490,923,004.16, up from CNY 293,152,306.72 in the previous year, reflecting a growth of approximately 67.3%[151]. Cash Flow and Assets - The net cash flow from operating activities was ¥337,780,624.10, reflecting a 5.31% increase from ¥320,744,856.25 in the previous year[25]. - The company's total assets at the end of the reporting period were ¥3,846,179,904.13, a 4.09% increase from ¥3,694,977,604.81 at the end of the previous year[25]. - Cash and cash equivalents decreased by ¥573,898,803.13, a decline of 40.83% compared to the previous period, mainly due to increased investments in bank financial products[44]. - The total cash and cash equivalents at the end of the period amounted to 908,816,393.15 yuan, down from 1,482,715,196.28 yuan at the beginning of the period[157]. - The company reported a decrease in cash and cash equivalents by -573,898,803.13 yuan, compared to -407,489,710.43 yuan in the previous period[157]. Business Operations - Revenue from the pharmaceutical sector amounted to 749 million yuan, accounting for 74.03% of the company's main business income[33]. - The pharmaceutical subsidiary, Dain Pharmaceutical, achieved a revenue growth of 27% year-on-year, with a net profit of 392 million yuan, up 66%[38]. - The company is focused on children's health products, with a product lineup that includes well-known brands like Yike Xin, which holds the largest market share in its category[34]. - Dain Pharmaceutical focuses on children's medicine and has improved production efficiency by importing core equipment from Germany and Italy, enhancing automation levels[67]. - The company is exploring strategic investments in raw material pharmaceutical companies to secure supply chains and mitigate risks associated with price reductions in children's medicines[67]. Research and Development - The company applied for a total of 33 intellectual property rights in the first half of 2021, with 18 being granted[38]. - Research and development expenses amounted to ¥29,827,217.69, showing a decrease of 4.67% from ¥31,288,647.52[44]. - Dain Pharmaceutical plans to continue enhancing research and innovation to diversify its children's medicine product offerings and strengthen its market position[67]. Governance and Compliance - The company is actively participating in state-owned enterprise reforms to optimize its governance structure and enhance operational efficiency[37]. - The company has not engaged in any significant related party transactions during the reporting period[91]. - There were no major litigation or arbitration matters during the reporting period[90]. - The company has adhered to all commitments made regarding competition avoidance and has completed relevant procedures[84]. Environmental Responsibility - The company has implemented an environmental self-monitoring plan, including online monitoring of wastewater discharge and regular third-party testing, with all results meeting standards[80]. - The company completed environmental impact assessments for its construction projects, with the first phase approved in November 2008 and environmental acceptance completed in December 2011[78]. - There were no administrative penalties due to environmental issues during the reporting period[81]. Shareholder Information - The company's stock structure includes 234,331,485 shares, with 99.93% being unrestricted shares[114]. - The largest shareholder, Shandong Huate Holding Group Co., Ltd., held 22.00% of the shares, totaling 51,544,340 shares[125]. - The total number of common shareholders at the end of the reporting period was 20,235[118]. - The company has not distributed any profits to shareholders, with a total profit distribution of -70,299,445.50[194].

Financial Performance - The company's operating revenue for the first quarter of 2021 was CNY 489,326,504.49, representing a 50.91% increase compared to CNY 324,257,077.01 in the same period last year[8] - Net profit attributable to shareholders was CNY 108,966,290.01, a significant increase of 119.85% from CNY 49,564,128.20 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 106,799,559.07, up 125.94% from CNY 47,269,118.36 in the previous year[8] - Basic earnings per share rose to CNY 0.47, reflecting a 123.81% increase from CNY 0.21 in the previous year[8] - Operating profit for the period was CNY 243,874,893.81, up from CNY 109,143,185.79, reflecting a growth of 123.8% year-over-year[52] - The total comprehensive income for the period was CNY 206,800,544.28, compared to CNY 94,077,184.44 in the previous year, reflecting a growth of 120.1%[54] Cash Flow - The net cash flow from operating activities reached CNY 136,767,795.21, an increase of 43.67% compared to CNY 95,198,529.80 in the same period last year[8] - Total cash inflow from operating activities was CNY 593,516,866.95, compared to CNY 451,424,861.50 in the previous year, indicating a growth of 31.4%[58] - The net cash flow from operating activities for Q1 2021 was -11,519,034.04 CNY, compared to -15,397,056.45 CNY in the same period last year[64] - Total cash inflow from operating activities was 49,223,639.54 CNY, an increase from 46,133,125.49 CNY year-over-year[61] - Cash outflow from operating activities totaled 60,742,673.58 CNY, slightly decreased from 61,530,181.94 CNY in the previous year[61] - The net cash flow from investing activities was -210,028,550.00 CNY, compared to -184,286,170.23 CNY in the previous year[64] - The company received 150,000,000.00 CNY from investment recoveries during the quarter[64] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,768,526,893.17, a 1.99% increase from CNY 3,694,977,604.81 at the end of the previous year[8] - The net assets attributable to shareholders increased to CNY 2,061,562,127.53, up 5.58% from CNY 1,952,595,837.52 at the end of the previous year[8] - Total liabilities decreased from ¥759,722,919.94 to ¥626,471,664.02, a reduction of about 17.5%[42] - Owner's equity rose to ¥3,142,055,229.15 from ¥2,935,254,684.87, indicating an increase of approximately 7.1%[42] - Total current liabilities decreased from ¥665,210,558.65 to ¥532,365,839.65, a decline of about 20%[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,998[12] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 2,166,730.94 during the reporting period[11] - The company's prepayments increased by 47.53% to CNY 38.90 million from CNY 18.49 million as of December 31, 2020[21] - Other receivables rose by 56.96% to CNY 17.69 million from CNY 10.08 million as of December 31, 2020[21] - The construction in progress surged by 421.11% to CNY 5.83 million from CNY 1.12 million as of December 31, 2020[21] - The company's tax payable increased by 190.06% to CNY 57.64 million from CNY 19.87 million as of December 31, 2020[21] - The company reported a significant decrease in investment income, down 97.81% to CNY 23.56 thousand from CNY 1.08 million in the previous period[21] - The company's cash and cash equivalents decreased to CNY 1.12 billion from CNY 1.49 billion as of December 31, 2020[38] - Cash and cash equivalents at the end of the period were 128,334,076.15 CNY, down from 133,402,255.97 CNY year-over-year[64] - The total cash outflow from financing activities was 49,103,527.00 CNY, compared to 52,214,397.33 CNY in the previous year[61] - The net increase in cash and cash equivalents was -221,547,584.04 CNY, compared to -199,683,226.68 CNY in the same period last year[64] - The company reported a decrease in sales expenses to CNY 55,289,527.55 from CNY 69,306,566.57, a reduction of 20.2% year-over-year[52] - Research and development expenses decreased to CNY 11,043,104.80 from CNY 12,899,187.55, a reduction of 14.4% year-over-year[52] Audit Information - The company has not undergone an audit for the Q1 2021 report[67]